Posts by: Patricia Inacio, PhD

News

The U.S. Food and Drug Administration has approved the immunotherapy Opdivo (nivolumab) as a treatment for two colorectal cancers that failed to respond to a chemotherapy combination, according to its developer, Bristol-Myers Squibb. Opdivo ... Read more

August 3, 2017

FDA Grants Breakthrough Therapy Status to Imfinzi for Unresectable NSCLC

News

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to Imfinzi (durvalumab) for patients with locally advanced, unresectable (unable to be removed with surgery) non-small cell lung cancer ... Read more

June 23, 2017July 4, 2017

Ilixadencel Provokes Strong Response Against Kidney Cancer, Phase 1/2 Clinical Trial Shows

News

Injecting ilixadencel into the tumors of newly diagnosed metastatic kidney cancer patients provoked a potent immune response to the disease, according to the first stage of a Phase 1/2 ... Read more

June 8, 2017

Early Data from Immunotherapy Studies in Advanced Cancer Patient Show Promise, Parker Institute Reports

News

Researchers at the Parker Institute for Cancer Immunotherapy have shown that the combination of Imfinzi (durvalumab) and tremelimumab, two immune checkpoint inhibitors, has a manageable safety profile and promising evidence of ... Read more

June 6, 2017

Insights into Yervoy and Target Molecule Has Potential for Improved Immunotherapies

News

Researchers unraveled the structure of interaction between immunotherapy drug Yervoy (ipilimumab) with its target molecule, and were able to build a three-dimensional model of the binding between the two. These results will ... Read more

June 5, 2017June 5, 2017

Genome Profiling May Help Predict Response to Keytruda in Head-Neck Cancer Patients

News

Profiling the genome of patients with head and neck squamous cell carcinoma (HNSCC) for mutations and interferon (IFN)-gamma-induced gene expression may independently predict patients’ response to immunotherapy with Keytruda ... Read more

May 18, 2017May 18, 2017

Vaccines Based on Immunotherapies Being Tested in Phase 2 Trials in Brain Cancer

News

Immunomic Therapeutics has entered an exclusive licensing agreement with Annias Immunotherapeutics for the rights to use Annia’s intellectual property regarding an immunotherapy based on antigens of cytomegalovirus (CMV). Both companies are developing new approaches for generating ... Read more

March 20, 2017March 20, 2017

Protein Known as Moesin Seen as Potential Target for Anti-Cancer Therapy in Early Study

News

In a preclinical study, researchers discovered that the protein moesin plays a key role in shutting down the immune response against cancer cells. These results support moesin as a ... Read more

August 18, 2016August 18, 2016

Researchers Discover How Immune System T-Cells Determine Function

News

Scientists have partially unlocked the mystery behind T-cell identification by showing how individual T-cells determine what their functions will be. The study “Tcf1 and Lef1 transcription factors establish CD8+ ... Read more

July 20, 2016July 20, 2016

Top Compounds to Boost Cancer Immunotherapies Identified by Insilico Medicine

News

Insilico Medicine has developed tools to analyze the molecular differences between patients who respond and fail to clinically approved immunotherapies based on checkpoints inhibitors. Immunotherapy has been successfully used to fight several ... Read more